Cerebrolysina

Precios por volumen

Precio por envase (10 viales). El descuento se aplica únicamente a este compuesto; no se admiten combinaciones.

Cerebrolysin — Multimodal Neuropeptide Complex / Pleiotropic Neurotrophic Agent

Cerebrolysin (FPF-1070) is a standardized, lipid-free neuropeptide preparation produced by enzymatic hydrolysis of purified porcine brain proteins. Unlike single-molecule peptides, Cerebrolysin is a complex mixture of low-molecular-weight neuropeptides (all below 10 kDa) and free amino acids whose active constituents include brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), glial cell line-derived neurotrophic factor (GDNF), ciliary neurotrophic factor (CNTF), and additional bioactive peptide fragments. Its small molecular size is the key to its most fundamental research advantage: the ability to cross the blood-brain barrier, a feat that most neurotrophic factors cannot accomplish when administered exogenously. This BBB permeability allows Cerebrolysin to deliver its multimodal neurotrophic and neuroprotective effects directly within the CNS.

Approved in over 45 countries for neurological indications including ischemic stroke, traumatic brain injury, and vascular dementia, Cerebrolysin has accumulated one of the most extensive clinical research records of any neuropeptide preparation — with data from more than 200 clinical trials and over 15,000 patients. It is not FDA-approved in the United States, where it remains a subject of active research interest.

Why Multimodal Neurotrophic Activity Matters

Most neuroprotective compounds target a single receptor, pathway, or mechanism. Cerebrolysin operates differently — its peptide complexity enables it to simultaneously engage multiple neurotrophic, neuroprotective, and neuroregenerative systems in a manner that mimics the endogenous neurotrophic factor network the brain deploys in response to injury or degeneration. Researchers describe this as a pleiotropic, multimodal mechanism — one that provides both immediate neuroprotection and long-term neuroregeneration through parallel pathway activation.

Aplicaciones de investigación

Cerebrolysin is used in studies examining:

• Neuroprotection and neurorecovery following acute ischemic and hemorrhagic stroke models
• Traumatic brain injury — mitigation of secondary injury cascades including inflammation, oxidative stress, and excitotoxicity
• Alzheimer’s disease models — amyloid burden reduction, APP processing regulation, and synaptic density preservation
• Vascular dementia — cognitive performance, cerebrovascular integrity, and neuroplasticity endpoints
• Neurogenesis and synaptic regeneration following acute and chronic CNS injury
• Microglial activation modulation and neuroinflammation resolution
• Cognitive function in aging models — memory, attention, and learning consolidation
• Spinal cord injury recovery and functional outcome endpoints
• Combination protocols with established pharmacological interventions for neurodegenerative conditions
• Tauopathy models — mitochondrial structural integrity and tau pathology progression

Especificaciones

Reconstitución

Cerebrolysin arrives as lyophilized powder and must be reconstituted with sterile or bacteriostatic water prior to use. Use the formula:

Total en mg ÷ Volumen añadido (mL) = Concentración (mg/mL)

Example: 60mg vial + 6mL sterile water = 10mg/mL solution

Reconstituted solution should be stored at 2–8°C and used within 28–30 days. Note: Clinical protocols have historically used intravenous administration for maximum CNS bioavailability; subcutaneous and intramuscular routes are also studied in research settings.

Notas sobre el protocolo

Cerebrolysin’s complex multi-peptide composition makes dose-response characterization a primary research focus. Clinical trial data consistently suggest that higher doses within the studied range (up to 30mL/day intravenous in clinical settings) produce more pronounced neurotrophic effects, while very high doses have shown diminishing returns in some models — making dose optimization a meaningful research variable. Duration of administration is similarly important, as downstream neuroplastic and regenerative effects accumulate over treatment courses rather than resolving with single administration.

Typical research dosing framework:

• Dose range: 5–30mg per administration depending on model and endpoint
• Frequency: Daily or near-daily administration in acute models; intermittent protocols studied for chronic neurodegeneration endpoints
• Routes studied: Intravenous (preferred for maximum BBB penetration and CNS bioavailability); intramuscular also studied in preclinical models
• Study duration: 2–4 weeks for acute injury models; 8–24 weeks for neurodegeneration and cognitive endpoints
• Combination protocols: Frequently studied alongside acetylcholinesterase inhibitors, antioxidants, and other neuroprotective agents

Efectos observados con frecuencia en modelos de investigación:

• CNS-related: Generally well tolerated; dizziness, headache, and mild fatigue reported in some clinical populations, typically transient and resolving with continued administration
• Systemic: Rare hypersensitivity reactions reported; injection site irritation with IM administration
• Safety context: No significant organ toxicity signals identified in clinical trial data; spontaneous adverse events requiring hospitalization reported at slightly higher rates vs. placebo in some stroke trials — an active area of ongoing safety characterization

Pilas de investigación

Cerebrolysin is commonly paired in research settings with:

• Semax — Semax is an ACTH-derived peptide that upregulates BDNF and NGF expression; pairing it with Cerebrolysin — which itself contains low-molecular-weight neurotrophic fragments — is studied in models examining cumulative neurotrophin availability and neuroprotective signaling.
• Selank — Selank modulates GABAergic and serotonergic tone while influencing BDNF expression; it is co-studied with Cerebrolysin in anxiety and cognitive models to assess complementary effects on monoamine signaling and synaptic plasticity.
• DSIP — Delta Sleep-Inducing Peptide influences hypothalamic regulatory circuits; it is paired with Cerebrolysin in neuroprotection research where sleep architecture and neural repair mechanisms are studied in parallel.

Garantía de pureza

Every batch is produced to standardized neuropeptide complex specifications. If you independently test your compound and the results don’t match our certificate of analysis — send us the COA and we’ll issue store credit, no questions asked.